Gilead Sciences' shares nose-dived after offering a weaker-than-expected sales outlook, primarily because of challenges in the company's Hepatitis C medicine.
, San Jose Mercury News: Business
Tue, 07/26/2016 - 12:06pm
Gilead Sciences' shares nose-dived after offering a weaker-than-expected sales outlook, primarily because of challenges in the company's Hepatitis C medicine.